Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
SNRNP70 regulates the splicing of CD55 to promote osteosarcoma progression
Wenyue Li, … , Yunyan Gu, Baofeng Yang
Wenyue Li, … , Yunyan Gu, Baofeng Yang
Published December 20, 2024
Citation Information: JCI Insight. 2024;9(24):e185269. https://doi.org/10.1172/jci.insight.185269.
View: Text | PDF
Research Article Cell biology Oncology

SNRNP70 regulates the splicing of CD55 to promote osteosarcoma progression

  • Text
  • PDF
Abstract

Osteosarcoma (OS) is the most common malignant bone tumor, characterized by a high propensity for metastasis. Recent studies have highlighted the role of alternative splicing in cancer metastasis, although the precise mechanisms underlying aberrant splicing in OS invasion and metastasis remain unclear. Here, we analyzed consistently differentially expressed genes and differentially alternative splicing events between primary and metastatic OS to identify potential genes associated with OS progression. U1 small nuclear ribonucleoprotein 70K (SNRNP70) emerged as both differentially expressed and spliced, with elevated SNRNP70 levels correlating with poor prognosis in pateints with OS. Functional experiments demonstrated that SNRNP70 overexpression enhanced the proliferation and metastasis of OS cells in vitro, while its depletion reduced these capabilities in vivo. Mechanistically, SNRNP70 directly interacted with CD55, modulating its alternative splicing and promoting tumor progression in OS. Additionally, metastatic OS samples exhibited increased infiltration of resting immune cells, and single-cell RNA sequencing revealed communication between SNRNP70-expressing osteoblastic cells and macrophages via the ADGRE5/CD55 signaling pathway. Overall, our results showed that SNRNP70 knockdown inhibited OS progression, which was associated with the splicing of CD55, indicating SNRNP70 as a promising target for OS treatment.

Authors

Wenyue Li, Linzhu Wang, Wen Tian, Weihang Ji, Danyang Bing, Yan Wang, Bingqian Xu, Jiayue Feng, Peng Zhang, Haihai Liang, Yunyan Gu, Baofeng Yang

×

Figure 4

CD55-Δe10 is crucial for the tumorigenicity of OS cells in vitro.

Options: View larger image (or click on image) Download as PowerPoint
CD55-Δe10 is crucial for the tumorigenicity of OS cells in vitro.
(A and...
(A and B) qRT-PCR analysis the efficiency of CD55-Δe10 overexpression in OS cells (n = 4). (C) The CCK-8 assay showing that CD55-Δe10 substantially enhanced cell viability (n = 6). (D and E) The wound-healing assay depicting the promoting effect of CD55-Δe10 overexpression on the migration (original magnification, × 40; n = 4). (F and G) The EdU assay showing that overexpressing CD55-Δe10 increased cell proliferation (scale bar: 50 μm; n = 4). (H and I) The Transwell assay showing the promoting effect of CD55-Δe10 overexpression on the invasiveness (scale bar: 100 μm; n = 4). (J and K) The colony formation assay illustrating the facilitating effect of CD55-Δe10 overexpression on the colony-forming capacity (n = 4). (L and M) qRT-PCR analysis the efficiency of CD55-Δe10 knockdown in OS cells (n = 4). (N) The CCK-8 assay for assessing the impact of CD55-Δe10 silencing on cell viability (n = 4). (O and P) The wound-healing assay to elucidate the inhibitory effects of silencing CD55-Δe10 on the migration (original magnification, × 40; n = 4). (Q and R) The EdU assay evaluating the cell proliferation after CD55-Δe10 knockdown (scale bar: 50 μm; n = 4). (S and T) The Transwell assay to assess the inhibitory effects of silencing CD55-Δe10 on the invasiveness (scale bar: 100 μm; n = 4). (U and V) The colony formation assay to evaluate the inhibitory effects of CD55-Δe10 knockdown on the colony-forming capacity (n = 4). Data are presented as mean ± SEM. Statistical significance was calculated using a 2-tailed Student’s t test (B, C, E, G, I, K, M, N, P, R, T, and V) or 1-way ANOVA followed by Dunnett’s multiple-comparison test (M). *P < 0.05; **P < 0.01; ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts